View Older Stories View More Recent Stories

Jun 6, 2016 09:03AM AbbVie (ABBV) Announces Additional Data on IMBRUVICA Phase 3 in CLL/SLL
Jun 6, 2016 09:00AM AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American S
Jun 6, 2016 06:26AM AbbVie (ABBV) Issues Positive Update on Rova-T as r/r SCLC Treatment
Jun 6, 2016 06:13AM AbbVie (ABBV) Announces Positive ABT-414 Phase 1 Data in Aggressive Brain Cancer
Jun 5, 2016 09:00AM AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meetin
Jun 5, 2016 07:30AM Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell L
Jun 3, 2016 08:12AM AbbVie (ABBV) Plans Pipeline Update at R&D Day Event; Includes IMBRUVICA, ABT-484 Data
Jun 3, 2016 08:09AM AbbVie to Highlight its Innovative Pipeline to the Investment Community
Jun 2, 2016 09:00AM AbbVie's Research and Commitment to Helping People Living with Rheumatologic Diseases Highlighted at the Annual European Congress of Rheumatology (EULAR 2016)
May 31, 2016 08:00AM AbbVie to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
May 31, 2016 07:23AM Biogen (BIIB), AbbVie (ABBV) Granted FDA Approval of ZINBRYTA for MS
May 31, 2016 06:19AM AbbVie (ABBV) Receives EC Approval of IMBRUVICA as CLL Treatment
May 31, 2016 06:00AM European Commission Approves IMBRUVICA® (ibrutinib) for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia
May 27, 2016 10:27PM Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
May 27, 2016 09:38PM Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple Sclerosis
May 27, 2016 09:36PM Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
May 27, 2016 07:09AM CHMP Issues Positive Opinion on AbbVie's (ABBV) HUMIRA as non-Infectious Uveitis Treatment
May 27, 2016 07:00AM AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1]
May 26, 2016 08:00AM AbbVie to Present at the Jefferies 2016 Healthcare Conference
May 24, 2016 11:00AM IL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in Patients with Moderate-to-Severe Crohn's Disease
May 19, 2016 08:00AM AbbVie's Leadership in Gastroenterology Showcased at Digestive Disease Week® with New HUMIRA® (adalimumab) Long-Term, Real-World Research and Promising Anti-IL-23 Antibody Late-Breaking Data
May 18, 2016 05:05PM AbbVie (ABBV) Announces Multiple Abstracts Evaluating Eight Medicines Across Cancer Types Presented at ASCO
May 18, 2016 05:00PM AbbVie Demonstrates Progress in Oncology Research at ASCO 2016 Annual Meeting with Multiple Abstracts Evaluating Eight Medicines Across Cancer Types
May 12, 2016 04:30PM AbbVie to Present at the UBS Global Health Care Conference
May 11, 2016 02:26PM Bristol-Myers Squibb (BMY), AbbVie (ABBV) Announce EC Approval of Empliciti Combo as Multiple Myeloma Treatment
May 11, 2016 02:25PM Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti™ (elotuzumab) for the Treatment of Multiple Myeloma in Adult Patients Who Have Received at Least One Prior Therapy
May 9, 2016 07:36AM AbbVie (ABBV) Announces FDA Update to IMBRUVICA Prescribing Info; Incldues Phase 3 Data for CLL
May 9, 2016 07:30AM U.S. FDA Expands IMBRUVICA® (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patie
Apr 29, 2016 09:19AM European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA® (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients
Apr 29, 2016 08:00AM AbbVie to Present at the Bank of America Merrill Lynch 2016 Global Health Care Conference
Apr 29, 2016 07:39AM Biogen (BIIB), AbbVie (ABBV) Receive Positive CHMP Opinion on ZINBRYTA in MS
Apr 29, 2016 07:39AM Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
Apr 28, 2016 07:21AM AbbVie (ABBV) to Acquire Stemcentrx in ~$5.8B Cash and Stock Deal
Apr 28, 2016 07:21AM AbbVie Reports First-Quarter 2016 Financial Results
Apr 28, 2016 07:20AM AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer
Apr 25, 2016 09:03AM AbbVie (ABBV) Receives FDA Approval of Viekira Pak sNDA for Use Without RBV
Apr 25, 2016 09:00AM AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic H
Apr 21, 2016 04:02PM CytomX (CTMX), AbbVie (ABBV) Enter Collaboration to Develop Probody Drug Conjugates Against CD71
Apr 21, 2016 04:01PM AbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates
Apr 21, 2016 04:01PM CytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates
Apr 21, 2016 06:28AM AbbVie (ABBV), argenx Enter Collaboration on ARGX-115 Against Novel Immuno-Oncology Target
Apr 21, 2016 01:07AM AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target
Apr 21, 2016 01:00AM argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target
Apr 20, 2016 08:35AM AbbVie (ABBV), University of Chicago Enter Cancer Research Collaboration
Apr 20, 2016 08:30AM AbbVie, University of Chicago collaborate to advance cancer research
Apr 20, 2016 08:13AM Biogen (BIIB), AbbVie (ABBV) Present Data at AAN Highlighting Impact of ZINBRYTA on Cognitive Outcomes and Targeted MOA
Apr 20, 2016 07:30AM Data Presented at AAN Highlight Impact of ZINBRYTA™ (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action
Apr 20, 2016 07:00AM AbbVie to Present at the Deutsche Bank 41st Annual Health Care Conference
Apr 18, 2016 06:46AM AbbVie (ABBV) Announces Positive Data from ABT-493, ABT-530 Phase 2 in HCV Genotypes 1 - 6 (ENTA)
Apr 16, 2016 01:00AM AbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-530 for Hepatitis C Genotypes 1-6
View More Recent Stories View Older Stories